Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).

@article{Infante2011PhaseIS,
  title={Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).},
  author={Jeffery R. Infante and Gerald Steven Falchook and Donald P. Lawrence and Jeff S Weber and Richard F Kefford and Johanna C. Bendell and Razelle Kurzrock and Gabriel D. Shapiro and Ragini Reiney Kudchadkar and Georgina V. Long and Ha. Burris and Kevin B Kim and Agnes Clements and Sharon Peng and Baojun Yi and Alicia Jones Allred and Danielle Ouellet and Kristofer Patel and Peter Fisher Lebowitz and Keith T Flaherty},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={CRA8503}
}
CRA8503 The full, final text of this abstract will be available in Part II of the 2011 Annual Meeting Proceedings, distributed onsite at the Meeting on June 4, 2011, and as a supplement to the June 20, 2011, issue of Journal of Clinical Oncology. 
BETA

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 63 CITATIONS, ESTIMATED 41% COVERAGE

Treatment algorithms in stage IV melanoma.

  • American journal of therapeutics
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2011
2018

CITATION STATISTICS

  • 2 Highly Influenced Citations

Similar Papers